The Surface Issue #2, April edition, was sent to all PSOLVE+ members by email on Monday, March 29, and can be accessed online here. This edition covers:
- Vaccine literacy amongst patients with psoriasis
- Pregnancy outcomes from the PSOLAR registry
- Bimekizumab phase 3 results in moderate-to-severe plaque psoriasis
- Targeting the IL-23/IL-17 pathway in plaque psoriasis
- Compassionately addressing teratogenic risk factors in the transgender population
- Real-world safety profile of acitretin in psoriasis patients
To view all issues of The Surface, go to https://psolve.org/the-surface/
